Company / Capital Expenditures
Neurocrine Biosciences Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$34.0M
FY2025
5-year range
$16.5M / $38.2M
FY2021-FY2025
Trend
-11.0%
vs FY2024
Sector context
#32 of 192
Health Care
What the data says
Neurocrine Biosciences's capital expenditures of $34M is higher than 83% of companies in the Health Care sector (FY2025). Capital Expenditures has fluctuated over the past 10 years, ranging from $4M in FY2016 to $38M in FY2024.
Based on SEC 10-K filings.
$34M in FY2025 with a 5-year CAGR of +25.5%. Top quartile in the Health Care sector.
Improved from $28M to $34M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +27.3%
- 5-Year CAGR
- +25.5%
- 10-Year CAGR
- -
Sector benchmark
-71.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +25.5%, indicating consistent growth.
- In FY2025, capital expenditures decreased 11.0% year-over-year.
- Ranks #32 out of 192 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $34.0M | -11.0% |
| FY2024 | $38.2M | +35.0% |
| FY2023 | $28.3M | +71.5% |
| FY2022 | $16.5M | -29.5% |
| FY2021 | $23.4M | +114.7% |
| FY2020 | $10.9M | -25.9% |
| FY2019 | $14.7M | -40.7% |
| FY2018 | $24.8M | +257.3% |
| FY2017 | $6.9M | +68.9% |
| FY2016 | $4.1M | +112.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026